Shares of Axsome Therapeutics were up after the company announced positive long-term results from a Phase III major depressive disorder (MDD) study that sets up potential regulatory approval for AXS-05.
A review of recently published scientific studies includes a look at the potential of using flu and pneumonia vaccines to decrease the risk of developing Alzheimer’s disease.
An experimental drug could offer hope for restoring damaged brain cells in Parkinson’s patients, scientists said on Wednesday, although they cautioned that a clinical trial was not able to prove the treatment slowed or halted the neurodegenerative disease.
Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer’s disease-associated genetic variants on the behavior of brain cells, called microglia.
The FDA approved Adamas Pharmaceuticals Inc’s treatment for a side effect caused by a commonly prescribed Parkinson’s drug.
Bristol-Myers Squibb Co. said it would license two of its drugs to Biogen Inc. and Roche Holding AG for an upfront fee of $470 million.
One in three people born in Britain in 2015 will develop dementia, according to an analysis commissioned by the charity campaign group Alzheimer’s Research UK. The study, conducted by the Office of Health Economics, shows “a looming national health crisis as the UK population ages”, the charity said, and underlines the need for global efforts […]
WASHINGTON, July 19, 2015 /PRNewswire-USNewswire/ — Promising early results of new drugs that target common components of several brain diseases that cause dementia – including Alzheimer’s disease, Parkinson’s disease, and Lewy Body dementia – were reported today at the Alzheimer’s Association International Conference® 2015 (AAIC® 2015) in Washington, D.C. These diseases cause a range of […]